Animal health products manufacturer Phibro Animal Health (NASDAQ: PAHC) reported calendar Q3 2026 (fiscal Q1 2027) results topping the market’s revenue expectations, with sales up 6.3% year on year to $386.8 million. The company expects the full year’s revenue to be around $1.58 billion, close to analysts’ estimates. Its non-GAAP profit of $0.79 per share was in line with analysts’ consensus estimates.

Is now the time to buy PAHC? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Phibro Animal Health’s latest quarter drew a modestly negative market reaction, despite revenue exceeding Wall Street expectations. Management highlighted that significant growth came from its non-animal health segments, with Performance Products and Mineral Nutrition expanding at double-digit rates. CEO Dani Bendheim acknowledged that animal health sales were softer than other segments, citing temporary demand pressures in poultry vaccines and nutritional specialties. Bendheim also noted that producer margins in protein markets tightened, leading some customers to trim spending and inventories. The company saw operating margin decline compared to the prior year, reflecting higher operating expenses and segment mix.

Looking ahead, management sees continued growth in the higher-margin portions of its Mineral Nutrition business and expects normalization in poultry demand as the year progresses. CEO Dani Bendheim indicated that any regulatory progress on virginiamycin sales in Brazil could represent upside to current expectations, though no such sales are assumed in the outlook. CFO Glenn David emphasized that inventory reduction and improved cash conversion are priorities, which could enhance flexibility for investment and debt reduction. External factors such as commodity price trends and livestock producer profitability remain key variables in performance for the rest of the year.

Key insights from management’s remarks

Management pointed to segment diversification and commodity pricing as central to the recent quarter’s growth, while noting operational cost pressures and temporary poultry market softness.

• Non-animal health momentum: Mineral Nutrition and Performance Products segments fueled most of the quarter’s growth, benefiting from higher demand and favorable pricing, especially for zinc, copper, and trace minerals. Management is shifting Mineral Nutrition toward plant nutrition, dairy, and pet food, aiming for higher margins and faster growth.
• Poultry segment headwinds: Nutritional specialties and vaccines in the animal health business declined due to lower poultry demand in North America and Brazil, compounded by cautious producer spending and inventory adjustments. Management expects this softness to be temporary, with normalization anticipated later in the year.
• Regulatory uncertainty in Brazil: Virginiamycin sales in Brazil dropped sharply as regulatory discussions continued without resolution. CEO Dani Bendheim said no virginiamycin sales are built into the annual outlook, but approval would provide incremental upside.
• Commodity cost impact: Volatility in feed and input prices, particularly related to corn and other grains, has pressured producer margins in protein markets. Management sees recent declines in corn prices as a potential tailwind for producers in the coming quarters, which could support demand for Phibro’s products.
• Inventory and cash flow focus: Management admitted to carrying excess inventory and outlined plans to prioritize inventory reduction and cash conversion. Improved cash flow is expected to enhance flexibility for investment, debt repayment, and potential returns to shareholders.

Drivers of future performance

Phibro’s outlook is shaped by ongoing recovery in poultry demand, regulatory milestones in Brazil, and continued margin pressure from input costs.

• Segment mix and demand recovery: Management expects higher-margin Mineral Nutrition products to drive growth as the company pivots toward plant nutrition, dairy, and pet food. Poultry demand is anticipated to rebound later in the year, supporting recovery in nutritional specialties and vaccines.
• Regulatory developments in Brazil: The company’s forecast does not include virginiamycin sales in Brazil, pending regulatory approval. Any progress on this front would be incremental to current guidance, with management maintaining an optimistic but cautious stance.
• Input cost and margin pressures: Feed and input commodity prices remain a significant factor for livestock producers. Lower corn prices are expected to ease cost pressures, but overall producer profitability is likely to stay soft in the near term. Management is monitoring these trends closely to assess their impact on customer purchasing behavior.

Catalysts in upcoming quarters

Going forward, the StockStory team will monitor (1) regulatory developments for virginiamycin in Brazil that could provide upside to sales, (2) progress on inventory reduction and improved cash conversion, and (3) the pace of recovery in poultry and livestock demand, especially as corn and feed costs evolve. Execution in shifting the Mineral Nutrition business to higher-margin segments will also be a key signpost.

Phibro Animal Health currently trades at $38.43, down from $39.43 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

High quality stocks for all market conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.